Genmab — April 2020
-
God morgen.
-
-
High rate of profound clonal and renal responses with Daratumumab treatment in heavily pre‐treated patients with AL amyloidosis and high bone marrow plasma cell infiltrate https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25828
-
Long term forecasts confirm Keytruda’s dominance https://www.evaluate.com/vantage/articles/data-insights/long-term-forecasts-confirm-keytrudas-dominance
-
Managing Multiple Myeloma During the COVID-19 Pandemic
A Conversation With C. Ola Landgren https://www.ascopost.com/news/april-2020/managing-multiple-myeloma-during-the-covid-19-pandemic/ -
Amivantamab er allerede på asco listen, så den er med på alm tilmelding. https://meetinglibrary.asco.org/session/12668
-
don't think, Jan van de Winkel gave up on one time milestones when he renegotiated the Arzerra deal
-
Genmab thereby got rid of participating in developement cost
-
it was in 2011 or so, when Genmab were in a very bad standing financially
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind